tradingkey.logo
tradingkey.logo

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

ReutersApr 29, 2025 12:16 PM

- Perspective Therapeutics Inc CATX.A:

  • PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH PSV359 IN A PHASE 1/2A STUDY IN PATIENTS WITH FAP-Α POSITIVE SOLID TUMORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI